Skip to main content

Recent News

Biologics Use and the Risk of Serious Infection in Psoriasis Patients

Oct 28, 2021

National Health Data from France examined biologic use in patients with moderate to severe psoriasis, and found the risk of serious infections (SIE) to be increased with some biologics (infliximab and adalimumab), but not others (etanercept, ustekinumab IL-17 and IL-23 inhibitors or apremilast).  Risk of serious infections was not increased for new users of secukinumab, ixekizumab, brodalumab, guselkumab, or apremilast vs etanercept, b

Read Article
FDA put a box warnings on breast implant packaging to include info that 1)Breast implants are not lifetime devices; 2) complication risk increases over time; 3) risk of anaplastic large cell lymphoma, 4) may be assoc w/ systemic Sxs https://t.co/VnpJg45PZY

Dr. John Cush @RheumNow (  View Tweet)

Oct 28, 2021
Rheumatoid Arthritis Thrombotic Risk Influenced by DMARD Choice https://t.co/gOLhO2aNOo https://t.co/FwKP3slExA
Dr. John Cush @RheumNow (  View Tweet)
Oct 28, 2021
QD Clinic - The Thyroid Lump QD Clinic is sponsored by https://t.co/V10S4oE43V's coverage of #ACR21 https://t.co/J5YkJmaNea https://t.co/UidG4dT1JJ
Dr. John Cush @RheumNow (  View Tweet)
Oct 28, 2021

Rheumatoid Arthritis Thrombotic Risk Influenced by DMARD Choice

Oct 27, 2021

RA patients have an increased risk of venous thromboembolism (VTE) related to disease activity and inflammation, yet a large real-world study of older RA patients shows methotrexate to be associated with a 2-fold increased VTE risk (compared to hydroxychloroquine).

Read Article

Platelet-Rich Plasma Injections Fail in Ankle Osteoarthritis

Oct 27, 2021

A controlled trial of intra-articular platelet-rich plasma (PRP) injections into the ankle of osteoarthritis (OA) patients failed to improve ankle symptoms and function when compared to placebo injections - yet another trial showing that intraarticular injections are seldom beneficial.

Read Article
Platelet-Rich Plasma Injections Fail in Ankle Osteoarthritis https://t.co/Fmf8f2C3Y4 https://t.co/9ZJe2jAYVw
Dr. John Cush @RheumNow (  View Tweet)
Oct 27, 2021
Sign up today to receive #ACR21 news and select topic emails throughout the conference. #RheumNow https://t.co/riyAnrRHhX https://t.co/MkoDsw34D0
Dr. John Cush @RheumNow (  View Tweet)
Oct 27, 2021
While psoriasis and Psoriatic arthritis patients have an increased risk of fractures, there is no increased risk of osteoporosis or osteopenia. Data from 12 studies an 199 million individuals https://t.co/G4Ya7CUWYX

Dr. John Cush @RheumNow (  View Tweet)

Oct 27, 2021
Systematic review of dsDNA studies (byfluorescence immunoassay) included 1977 total patients, 47% with SLE == over all dsDNA had >90% for specificity and a pooled specificity of 94.7% (95% CI 91.67%-96.67%) https://t.co/Nk8h9fDYpE

Dr. John Cush @RheumNow (  View Tweet)

Oct 27, 2021
Methotrexate is the most often-studied treatment and has best clinical outcomes in children and adults with localized scleroderma en coup de sabre. Metanalysis of 34 articles, only 4 RCTs, but 24 case reports. More research needed. https://t.co/fSEvDw2pge

Dr. John Cush @RheumNow (  View Tweet)

Oct 27, 2021

Pfizer/Lilly Pull Tanezumab Development

Oct 26, 2021

Today, Lilly and Pfizer announced their global clinical development of the NGF inhibitor, tanezumab, has been discontinued due to recent negative opinions from the EMA and FDA advisory committee.

This decision mirrors that of other companies (AbbVie, AstraZeneca, Johnson & Johnson) who, in the last 10 years, have halted NGF inhibitor development due to FDA concerns over risk/benefit in patients with osteoarthritis.  

Read Article
Register now to receive #ACR21 news and select topic emails throughout the conference. https://t.co/riyAnrRHhX https://t.co/ufGxXnbtoG
Dr. John Cush @RheumNow (  View Tweet)
Oct 26, 2021
Rheumatic pts admitted to ICU, #SLE is most common & Sepsis most common reason. 80 ARD pts adm to ICU: Dx were SLE (42%), RA (26%), vasculitis (12%) FOR Sepsis (31%), (10%) CHF (10%). 20% died in ICU, 5% 30d after ICU, 7.5% w/in 1 yr https://t.co/lX0m3vOukI

Dr. John Cush @RheumNow (  View Tweet)

Oct 26, 2021
Short (3 min) walks intstead of sitting benefits RA w/ anticytokine effect (TNF, IL1RA), improved glucose, c-peptide, insulin. Crossover study 15 RA women who had 1) prolonged sitting, 2) 30-min mod-vigor exercise or 3) 3-min of light walking every 30 min https://t.co/36AnhHL9OI

Dr. John Cush @RheumNow (  View Tweet)

Oct 26, 2021
New Download Available! FDA EUA for Baricitinib in COVID https://t.co/yTQLb7DDvR https://t.co/n9Npg0Pq5q
Dr. John Cush @RheumNow (  View Tweet)
Oct 26, 2021
Watch: QD Clinic - Severe Arthritis Numbers QD Videos are brought to you by RheumNow's upcoming coverage of ACR 2021 https://t.co/QgBL4dnCk7

Dr. John Cush @RheumNow (  View Tweet)

Oct 26, 2021
From March to Dec 2020, study of 116K COVID pts saw monthly rates of hospitalization (105/100K), ICU admits (20/100K), & death (12/100K) -peaked 12/20. Highest w/ age >65yrs, hispanics, blacks. Remdesivir incr 1.7% to 54%; Steroids 19% to 74.2% https://t.co/5pzu74YIz6

Dr. John Cush @RheumNow (  View Tweet)

Oct 26, 2021

New Hope for NonAlcoholic Fatty Liver Disease

Oct 25, 2021

The current issue of the NEJM has two articles on nonalcoholic fatty liver disease (NAFLD also called NASH - nonalcoholic steatohepatitis), one dealing with the prognoses, outcomes and mortality of NAFLD and another prospective and promising interventional trial in NASH patients. 

Read Article

How Should Patients With Autoimmune Diseases Approach COVID Vaccination?

MedPage Today
Oct 25, 2021

Healthcare is a personal and individualized relationship between a provider and patient. Each patient is treated according to their particular symptoms and personal health characteristics. For this reason, the wide variability in patient responses to the same medical treatments must be acknowledged and accounted for in making public health decisions.

Read Article
×